KLRAKailera Therapeutics, Inc.
- Market cap
- $1.67B
- as of 2026-10-23
- Latest close
- $12.85
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2026-04-20
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Nicholson NurChief Technology Officer | Sep 7 | Sep 9 | A · derivative | 220,000 | $16.23 | $3,570,600 | 220,000 | No | Form 4 |
| Tregoning KathleenSee Remarks | Jul 6 | Jul 8 | A · derivative | 175,000 | $23.30 | $4,077,500 | 175,000 | No | Form 4 |
| Renaud Ronald C JRCEO & President | Jun 9 | Jun 11 | M | 38,094 | $5.25 | $199,994 | 38,094 | No | Form 4 |
| Renaud Ronald C JRCEO & President | Jun 9 | Jun 11 | M · derivative | 38,094 | $5.25 | $199,994 | 817,826 | No | Form 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Apr 20 | Apr 22 | C | 9,477,719 | not reported | not reported | 9,477,719 | No | Form 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Apr 20 | Apr 22 | C | 2,034,133 | not reported | not reported | 2,034,133 | No | Form 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Apr 20 | Apr 22 | C · derivative | 4,968,789 | $0.00 | $0 | not reported | No | Form 4 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Apr 20 | Apr 22 | C · derivative | 708,814 | $0.00 | $0 | not reported | No | Form 4 |
| Rtw Investments, LP | Apr 20 | Apr 22 | C | 10,276,820 | not reported | not reported | 10,276,820 | No | Form 4 |
| Rtw Investments, LP | Apr 20 | Apr 22 | P | 500,000 | $16.00 | Purchase +$8,000,000 | 10,776,820 | No | Form 4 |
| Rtw Investments, LP | Apr 20 | Apr 22 | C · derivative | 8,250,000 | not reported | not reported | not reported | No | Form 4 |
| Rtw Investments, LP | Apr 20 | Apr 22 | C · derivative | 2,026,820 | not reported | not reported | not reported | No | Form 4 |
| Kaplan Andrew T. | Apr 20 | Apr 20 | C | 17,857,143 | not reported | not reported | 17,857,143 | No | Form 4 |
| Kaplan Andrew T. | Apr 20 | Apr 20 | P | 8,398,438 | $16.00 | Purchase +$134,375,008 | 26,255,581 | No | Form 4 |
| Kaplan Andrew T. | Apr 20 | Apr 20 | C · derivative | 17,857,143 | $0.00 | $0 | not reported | No | Form 4 |
| BCLS Fund IV Investments GP, LLC | Apr 20 | Apr 20 | C | 16,875,000 | not reported | not reported | 16,875,000 | No | Form 4 |
| BCLS Fund IV Investments GP, LLC | Apr 20 | Apr 20 | C | 4,145,768 | not reported | not reported | 21,020,768 | No | Form 4 |
| BCLS Fund IV Investments GP, LLC | Apr 20 | Apr 20 | P | 1,562,500 | $16.00 | Purchase +$25,000,000 | 22,583,268 | No | Form 4 |
| BCLS Fund IV Investments GP, LLC | Apr 20 | Apr 20 | C · derivative | 16,875,000 | $0.00 | $0 | not reported | No | Form 4 |
| BCLS Fund IV Investments GP, LLC | Apr 20 | Apr 20 | C · derivative | 4,145,768 | $0.00 | $0 | not reported | No | Form 4 |
| Koppel Adam | Apr 20 | Apr 20 | C | 16,875,000 | not reported | not reported | 16,875,000 | No | Form 4 |
| Koppel Adam | Apr 20 | Apr 20 | C | 4,145,768 | not reported | not reported | 21,020,768 | No | Form 4 |
| Koppel Adam | Apr 20 | Apr 20 | P | 1,562,500 | $16.00 | Purchase +$25,000,000 | 22,583,268 | No | Form 4 |
| Koppel Adam | Apr 20 | Apr 20 | C · derivative | 16,875,000 | $0.00 | $0 | not reported | No | Form 4 |
| Koppel Adam | Apr 20 | Apr 20 | C · derivative | 4,145,768 | $0.00 | $0 | not reported | No | Form 4 |
| BCPE Perseus Investor, LP | Apr 20 | Apr 20 | C | 17,857,143 | not reported | not reported | 17,857,143 | No | Form 4 |
| BCPE Perseus Investor, LP | Apr 20 | Apr 20 | P | 8,398,438 | $16.00 | Purchase +$134,375,008 | 26,255,581 | No | Form 4 |
| BCPE Perseus Investor, LP | Apr 20 | Apr 20 | C · derivative | 17,857,143 | $0.00 | $0 | not reported | No | Form 4 |
| Pagan Douglas W.Chief Financial Officer | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Pagan Douglas W.Chief Financial Officer | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Clyburn Frank | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |
| Hite Christopher | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |
| Wasserman Scott M.Chief Medical Officer | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Wasserman Scott M.Chief Medical Officer | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Mackay Martin | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |
| Coleman Jamie BethChief Commercial Officer | Apr 16 | Apr 20 | A · derivative | 75,000 | $16.00 | $1,200,000 | 75,000 | No | Form 4 |
| Coleman Jamie BethChief Commercial Officer | Apr 16 | Apr 20 | A · derivative | 75,000 | $16.00 | $1,200,000 | 75,000 | No | Form 4 |
| Milligan John F | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |
| Burgess Paul D.See Remarks | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Burgess Paul D.See Remarks | Apr 16 | Apr 20 | A · derivative | 100,000 | $16.00 | $1,600,000 | 100,000 | No | Form 4 |
| Renaud Ronald C JRCEO & President | Apr 16 | Apr 20 | A · derivative | 300,000 | $16.00 | $4,800,000 | 300,000 | No | Form 4 |
| Renaud Ronald C JRCEO & President | Apr 16 | Apr 20 | A · derivative | 300,000 | $16.00 | $4,800,000 | 300,000 | No | Form 4 |
| Akamine ScottChief Legal Officer | Apr 16 | Apr 20 | A · derivative | 60,000 | $16.00 | $960,000 | 60,000 | No | Form 4 |
| Akamine ScottChief Legal Officer | Apr 16 | Apr 20 | A · derivative | 60,000 | $16.00 | $960,000 | 60,000 | No | Form 4 |
| Cloghessy PaulaChief People Officer | Apr 16 | Apr 20 | A · derivative | 60,000 | $16.00 | $960,000 | 60,000 | No | Form 4 |
| Cloghessy PaulaChief People Officer | Apr 16 | Apr 20 | A · derivative | 60,000 | $16.00 | $960,000 | 60,000 | No | Form 4 |
| Kaplan Andrew T. | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |
| Koppel Adam | Apr 16 | Apr 20 | A · derivative | 38,300 | $16.00 | $612,800 | 38,300 | No | Form 4 |